Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agalsidase beta biosimilar - JCR Pharmaceuticals/GSK

Next Previous
Drug Profile

Agalsidase beta biosimilar - JCR Pharmaceuticals/GSK

Alternative Names: Agalsidase Beta BS I.V. Infusion [JCR]; Alpha-galactosidase A - JCR/GSK; JR-051

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JCR Pharmaceuticals
  • Class Galactosidases; Glycoproteins; Isoenzymes; Recombinant proteins
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 02 Oct 2025 JCR Pharmaceuticals enters into a licensing agreement with Menagen Pharmaceutical Industries to seek local marketing authorisations and to commercialise Agalsidase Beta biosimilar
  • 19 Jun 2020 Efficacy and adverse events data from a phase II/III trial in Farbry's disease released by JCR Pharmaceuticals
  • 30 Nov 2018 Launched for Fabry's disease in Japan (IV) - First global launch

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top